| scholarly article | Q13442814 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Mauro Galeazzi | Q73480279 | ||
| Ronald H. W. M. Derksen | Q73744763 | ||
| Euro-Phospholipid Project Group | Q114291036 | ||
| Pier Luigi Meroni | Q38544871 | ||
| Ricard Cervera i Segura | Q53547424 | ||
| Antonio Fernandez-Nebro | Q54165674 | ||
| Carlos Vasconcelos | Q56750258 | ||
| Gerard Espinosa | Q60326205 | ||
| Zahir Amoura | Q69662859 | ||
| Angela Tincani | Q73304219 | ||
| Munther A. Khamashta | Q73418907 | ||
| Stefano Bombardieri | Q73477457 | ||
| P2093 | author name string | R Serrano | |
| S Jacobsen | |||
| G J Pons-Estel | |||
| T Tarr | |||
| E Hachulla | |||
| E de Ramón | |||
| M Mosca | |||
| L Ceberio-Hualde | |||
| V Buonaiuto | |||
| F Bellisai | |||
| M Baleva | |||
| J-C Gris | |||
| F Houssiau | |||
| M Miyara | |||
| M Haro | |||
| E Nomikou | |||
| I Quéré | |||
| M L Bertolaccini | |||
| M Taglietti | |||
| M Tektonidou | |||
| G Theodossiades | |||
| M M Zeher | |||
| P G D de Groot | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| antiphospholipid syndrome | Q582207 | ||
| P304 | page(s) | 1011-1018 | |
| P577 | publication date | 2014-01-24 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | |
| P478 | volume | 74 |
| Q94453403 | A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| Q57057038 | Acute Kidney Injury in Pregnancy: The Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Prevention and Care of Pregnancy-Related AKI, in the Year Dedicated to Women and Kidney Diseases |
| Q93127155 | An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers |
| Q96304889 | An update on the management of antiphospholipid syndrome |
| Q92639094 | Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery |
| Q38753862 | Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes |
| Q90312460 | Antiphospholipid Syndrome and Kidney Involvement: New Insights |
| Q52368982 | Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. |
| Q30235423 | Antiphospholipid syndrome |
| Q64046338 | Antiphospholipid syndrome |
| Q48567974 | Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess |
| Q51140007 | Antiphospholipid syndrome in Sarawak: real world experience in a developing country. |
| Q24185813 | Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome |
| Q40323287 | Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). |
| Q55479438 | Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. |
| Q91622628 | Associated clinical factors for serious infections in patients with systemic lupus erythematosus |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q36303250 | Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant |
| Q33419886 | Catastrophic APS in the context of other thrombotic microangiopathies |
| Q64101902 | Cerebellar Atrophy and Neurocognitive Disorder as Primary Presentation of Antiphospholipid Syndrome in a Young Male |
| Q33431396 | Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events |
| Q38657043 | Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers |
| Q47685633 | Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients |
| Q97426362 | Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review |
| Q64092966 | Complement in the Pathophysiology of the Antiphospholipid Syndrome |
| Q55035223 | Coronary Artery Thromboses, Stent Thrombosis and Antiphospholipid Antibody Syndrome: Case Report. |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q41103646 | Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops |
| Q39449741 | Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment |
| Q92983632 | Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance |
| Q38868618 | Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome? |
| Q33434719 | Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study |
| Q38736953 | Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study. |
| Q89588653 | Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study |
| Q58572438 | Etiologies des accidents vasculaires cérébraux ischémiques chez les jeunes: apport de l’interniste |
| Q90428389 | FcRn augments induction of tissue factor activity by IgG-containing immune complexes |
| Q58776407 | Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome |
| Q90286503 | Heterogeneity in neutrophil responses to immune complexes |
| Q58608546 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome |
| Q90115791 | Idiopathic Normal Pressure Hydrocephalus - What We Know |
| Q65001136 | Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study. |
| Q40115024 | Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. |
| Q92124996 | Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the NOH-APS cohort |
| Q47372819 | Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review |
| Q93185027 | Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature |
| Q48328781 | Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q50640109 | Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. |
| Q90120568 | Management of stroke and pregnancy |
| Q93060997 | Managing antiphospholipid syndrome in pregnancy |
| Q53773313 | Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study. |
| Q92490435 | Mixed connective tissue disease in pregnancy: A case series and systematic literature review |
| Q38753531 | Musculoskeletal manifestations of the antiphospholipid syndrome |
| Q88417083 | Myocardial function in primary antiphospholipid syndrome using speckle-tracking echocardiography |
| Q33418245 | Neonatal outcome in pregnant patients with antiphospholipid syndrome |
| Q39106759 | New Insights in the Pathophysiology of Antiphospholipid Syndrome. |
| Q90567970 | Nine-test panel has superior sensitivity to detect antiphospholipid antibody syndrome in patients with or without SLE |
| Q38753510 | Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. |
| Q89069700 | Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? |
| Q38697342 | Organ Damage and Quality of Life in Antiphospholipid Syndrome. |
| Q49723590 | Painful recurrent leg ulcers |
| Q89986376 | Pediatric APS: State of the Art |
| Q91715407 | Pediatric antiphospholipid syndrome |
| Q90261755 | Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge |
| Q37137892 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy |
| Q89724842 | Precision medicine and the antiphospholipid syndrome: what is the future? |
| Q90115787 | Pregnancy Management in Women with Antiphospholidic Syndrome |
| Q59791491 | Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome |
| Q91854110 | Primary Antiphospholipid Antibody Syndrome Complicated with Cerebellar Hemorrhage and Aortic Dissection: A Case Report |
| Q64959086 | Safety of retrievable inferior vena cava filters in patients with the antiphospholipid syndrome. |
| Q92150707 | Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study |
| Q37204282 | Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome |
| Q92667904 | Stratifying management of rheumatic disease for pregnancy and breastfeeding |
| Q47636314 | Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement |
| Q89099582 | Survival Analysis of Turkish Patients With Systemic Lupus Erythematosus: Older Age at Diagnosis Affects Mortality |
| Q35530248 | Systemic lupus erythematosus and thrombosis |
| Q59807283 | The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome |
| Q35909733 | The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse |
| Q88399624 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository |
| Q96135566 | The Issue of the Antiphospholipid Antibody Syndrome |
| Q36928593 | The antiphospholipid syndrome: still an enigma |
| Q33419972 | The challenge of bleeding in antiphospholipid antibody-positive patients |
| Q48005192 | The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome |
| Q26765406 | The role of anti-phospholipid antibodies in autoimmune reproductive failure |
| Q26866133 | The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome |
| Q87420220 | Therapy: Antiphospholipid syndrome research needs more collaboration |
| Q33434497 | Thrombocytopenic syndromes in pregnancy |
| Q26739950 | Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay |
| Q33443108 | Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study |
| Q38755260 | Treatment of catastrophic antiphospholipid syndrome |
| Q64990886 | Two Faces of the Same Coin: A Case Report of Antiphospholipid Syndrome Nephropathy. |
| Q64086736 | Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
| Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
| Q48035289 | Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy? |
| Q86403330 | [What's new in internal medicine?] |
Search more.